Months after the outbreak of a new flu‐like disease in China, the entire world is now in a state of caution. The subsequent less‐anticipated propagation of the novel coronavirus disease, formally known as COVID‐19, not only made it to headlines by an overwhelmingly high transmission rate and fatality reports, but also raised an alarm for the medical community all around the globe. Since the causative agent, SARS‐CoV‐2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID‐19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.
Context: The novel coronavirus disease (COVID-19) is one of the most threatening pandemics in history involving multiple organs, including the kidney. This study aimed to review the association of COVID-19 with renal involvement. Evidence Acquisition: International databases, including the Web of Science, PubMed, Scopus, and Google Scholar, were searched for articles by April 1, 2020. Keywords were COVID-19, coronavirus disease, SARS-CoV-2, kidney, renal function, acute kidney injury, and acute renal failure, or a combination of them in title/abstracts. Results: There were a few studies concerning COVID-19 and renal failure due to the short time elapsed from the epidemic onset. The results showed that hematuria and proteinuria were common in patients with COVID-19. Conclusions: Patients with elevated creatinine are at risk of mortality two times more than patients with normal creatinine. Also, elevated BUN, proteinuria, and hematuria can increase the risk of mortality in patients with COVID-19 up to four times compared to patients with normal tests. Therefore, it is important to check creatinine, BUN, proteinuria, and hematuria in primary assessments. Generally, all routine measures for people affected with COVID-19 can be done for COVID-19 patients with acute renal failure until the current knowledge is changed. Chloroquine phosphate may improve the chance of treatment.
COVID-19 is spreading all around the world, and is considered as the most widespread infectious disease of the century. Coronavirus transmits through respiratory droplets when in close contact with the infected person. Therefore, populous places are more likely to be the source of the novel coronavirus that is threatening the health of everyone especially the geriatric population. This study aimed to compare the transmission of coronavirus between metropolitan and non- metropolitan counties as lessons of mortality (especially in geriatric) following COVID-19 epidemic. The USAFact.org public website (https://usafacts.org/visualizations) was used to determine the transmission between metro and non- metropolitan counties. In this study, four different time periods were considered for the COVID-19 incremental trend (April 1, May 1, June 1, and July 1, 2020). The number of cases was determined per each 10,000 population. Yellow color means no case in the metropolitan county (metro). Orange color means less than 10 cases/10,000 of the population in metro. Figure and maps were used to show the objectives of the study. In metropolitan counties, the spread of COVID-19 is very fast, which is significantly different from the non-metro counties (P<0.001). The results show the sharp increasing trend of infected people in metropolitan counties. In metropolitan counties the number of infected people reached 2 420 316 cases per 10 000 populations but the number of infected people reached 231 459 cases per 10 000 populations. Over the four months period, the frequency of the light colors was decreased. According to the results, susceptible people especially the elderly should move to non- metropolitan counties during the COVID-19 pandemic to be less likely at risk.
Emerging coronavirus-related respiratory disease started from Wuhan, China in December 2019 resulted in numerous mortality following acute respiratory distress syndrome (ARDS) named COVID-19 disease. The incubation period of COVID-19 is varied from 2 days to 2 weeks; therefore oral transmission is the most hazardous issue in this incubation period. Scientists are trying to find a specific drug to treat COVID-19 disease, however there is no specific therapy yet. One of the challenging issues in the treatment process of these patients is ARDS. In the development of any type of pneumonia or ARDS, Covid-19 should be considered as an option for differential diagnosis and the first critical organ in these patients is lung. In this paper, we discussed ARDS in patients with COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.